At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease
In Brief
A Phase 4 clinical trial evaluating Lanthanum carbonate, placebo, and 5 other interventions for Chronic Kidney Disease and Cardiovascular Disease. Completed, enrolled 66 participants across 1 site.
Detailed Summary
The proposed research is a randomized-controlled trial to determine the effectiveness of reducing serum phosphorus using a phosphate binder, lanthanum carbonate, for improving the function of arteries in adults with moderate to severe chronic kidney disease (CKD). \[COMIRB 13-0328\] Additionally, it will determine phosphorus balance among adults with CKD and whether there is a difference in phosphorus balance after three months of treatment with lanthanum carbonate. \[COMIRB 15-0384\]
Study Details
Timeline
Interventions
Non-calcium containing phosphorus binder
Table identical to lanthanum carbonate but with no active ingredient
Intravenous administration during measurement of flow mediated dilation.
Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.